Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cases Miner Bone Metab. 2009 May;6(2):163-8.

Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.

Author information

1
Division of Bone Diseases [WHO Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Abstract

BACKGROUND:

Sex hormones are important regulators of calcium and phosphate homeostasis. Estradiol appears to be a major determinant of bone health in the male gender. However, physiological effects of estrogens on calcium and phosphate homeostatic fluxes in men are still poorly understood.

OBJECTIVE:

We investigated the influence of 6 weeks of the SERM raloxifene, an estrogen agonist in bone, but devoid of feminizing actions, on calcium and phosphate metabolism in healthy middle-aged men.

DESIGN:

In a double-blind, randomized, placebo-controled, cross-over study, we evaluated the influence of 120 mg/day of raloxifene on calciotropic hormones levels, renal tubular reabsorption of calcium and phosphate, and intestinal calcium absorption, as assessed by the calciuric response to an oral calcium load.

RESULTS:

As compared to the placebo period, raloxifene treatment decreased the response to an oral calcium load, together with a decrease in 1,25(OH)(2)D(3) and in IGF-I serum levels. Maximal renal tubular phosphate reabsorption was decreased in raloxifene-treated men following the calcium load. The renal handling of calcium was not changed.

CONCLUSION:

These results are compatible with the hypothesis that raloxifene is associated with lower IGF-I and 1,25(OH)(2)D(3) levels, with consequently reduced intestinal calcium absorption capacity.

PMID:
22461168
PMCID:
PMC2781229
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center